Table 4.
Descriptives of the Braining Pilot Cohort; metabolic parameters, psychiatric assessment scales, somatic diagnoses, occupational status, neuropharmaceuticals
| Braining Pilot Cohort | |
|---|---|
| N | 51 |
| Metabolic parameters, mean (SD) | |
| fP-HDL-cholesterol | 1.40 (0.42) |
| fP-LDL-cholesterol | 3.37 (0.94) |
| fP-cholesterol | 5.34 (1.01) |
| fP-triglycerides | 1.54 (0.77) |
| P-glucose | 5.80 (0.98) |
| Systolic blood pressure | 128.07 (17.09) |
| Diastolic blood pressure | 81.37 (11.31) |
| Psychiatric assessment scales, mean (SD) | |
| PHQ-9 | 12.55 (8.16) |
| GAD-7 | 10.45 (5.80) |
| CGI-S | 3.42 (1.44) |
| EQ-5D-5L | 0.64 (0.21) |
| EQ-5D-3L | 0.52 (0.27) |
| EQ 5D general health | 47.98 (26.35) |
| Prevalent somatic diagnoses, n (%) | |
| Diabetes | 3 (5.9) |
| Hyperlipidemia | 3 (5.9) |
| Hypertension | 14 (27.5) |
| Asthma | 3 (5.9) |
| Pain conditions | 18 (35.3) |
| Cancer | 7 (13.7) |
| Occupational status, n (%) | |
| Full-time work | 6 (11.8) |
| Sick-leave, full- or part-time | 32 (62.7) |
| Retirement | 10 (19.6) |
| Missing | 3 (5.9) |
| Neuropharmaceuticals (by ATC code), n (%) | |
| Antipsychotics (exkl lithium) | 25 (50.0) |
| Lithium | 14 (27.5) |
| Antidepressants | 33 (64.7) |
| Anxiolytics (excl. bensodiazepines) | 2 (3.9) |
| Bensodiazepines | 11 (21.6) |
| Hypnotics and sedatives (excl. bensodiazepine derivates and benzodiazepine related drugs) | 15 (29.4) |
| Bensodiazepine derivates and benzodiazepine related drugs | 22 (43.1) |
| Psychostimulants | 5 (9.8) |
| Antiepileptics | 13 (25.5) |
| Antihistamines | 17 (33.3) |
| Opioids | 4 (7.8) |
| Other | |
| Physical Activity on Prescription (%) | 19 (37.3) |